MedPath

LIVERPOOL SCHOOL OF TROPICAL MEDICINE

🇬🇧United Kingdom
Ownership
-
Established
1898-01-01
Employees
650
Market Cap
-
Website
https://www.lstmed.ac.uk/

Clinical Trials

47

Active:1
Completed:16

Trial Phases

5 Phases

Phase 1:2
Phase 2:4
Phase 3:6
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials

Not Applicable
18 (50.0%)
Phase 3
6 (16.7%)
Phase 4
6 (16.7%)
Phase 2
4 (11.1%)
Phase 1
2 (5.6%)

Safety of Antimalarials in the FIRst trimEster

Phase 3
Not yet recruiting
Conditions
Malaria, Pregnancy
Malaria, Antepartum
Malaria (Uncomplicated)
Interventions
Drug: Pyronaridine-artesunate (PA)
Drug: dihydroartemisinin-piperaquine (DP)
First Posted Date
2025-05-08
Last Posted Date
2025-05-08
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
1510
Registration Number
NCT06962319
Locations
🇧🇫

Clinical Research Unit of Nanoro (CRUN), Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO), Nanoro, Burkina Faso

🇰🇪

KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya

🇲🇱

Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako (USTTB),, Bamako, Mali

Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome

Not yet recruiting
Conditions
Haemorrhagic Fever With Renal Syndrome
First Posted Date
2025-04-25
Last Posted Date
2025-04-25
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
62
Registration Number
NCT06944275

Development of a Rapid Diagnostic Test to Identify Crimean-Congo Hemorrhagic Fever - Research and Development Testing

Not yet recruiting
Conditions
Infectious Diseases, Emerging
First Posted Date
2025-03-25
Last Posted Date
2025-03-25
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
200
Registration Number
NCT06894758
Locations
🇹🇷

Ondokuz Mayis University (OMU) Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Samsun, Samsun, Turkey

🇹🇷

Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Sivas Cumhuriyet University, Sivas, Sivas, Turkey

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Phase 2
Not yet recruiting
Conditions
Crimean-Congo Hemorrhagic Fever
Interventions
Other: Optimised Standard of Care
Drug: Ribavin
First Posted Date
2025-03-06
Last Posted Date
2025-03-06
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
378
Registration Number
NCT06860334

Mapping Snakebite Risk in Ghana and Rwanda

Not yet recruiting
Conditions
Snakebite
Snake Envenomation
First Posted Date
2025-02-05
Last Posted Date
2025-02-05
Lead Sponsor
Liverpool School of Tropical Medicine
Target Recruit Count
32000
Registration Number
NCT06808789
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

News

Breakthrough Universal Antivenom Developed Using Blood of Man Bitten 200+ Times

Scientists have developed a groundbreaking antivenom using antibodies from Tim Friede, who voluntarily endured over 200 snake bites and 700 venom injections over nearly 20 years.

£10M Investment in AI-Powered Robotic Labs to Accelerate Infectious Disease Treatment Development

Liverpool School of Tropical Medicine receives £10M funding to establish AI-powered robotic Containment Level 3 laboratories for accelerating development of treatments for high-risk infectious diseases.

Nitisinone Shows Promise as Novel Malaria Control Strategy by Making Human Blood Lethal to Mosquitoes

Researchers have discovered that nitisinone, a drug used to treat rare genetic disorders, makes human blood toxic to mosquitoes that transmit malaria, offering a potential new control strategy.

© Copyright 2025. All Rights Reserved by MedPath